Astrazeneca (AZN) Cash from Operations (2009 - 2026)

Astrazeneca has reported Cash from Operations for 18 years, with the latest figure at $2.9 billion in Q2 2026.

• On a quarterly basis, Cash from Operations fell 15.39% year-over-year to $2.9 billion in Q2 2026; TTM through Jun 2026 was $13.7 billion, a 2.32% increase from a year earlier, with the FY2025 full-year figure at $14.6 billion, up 22.88% from the prior year.
• Cash from Operations was $2.9 billion for Q2 2026 at Astrazeneca, down from $3.4 billion in the prior quarter.
• The five-year high for Cash from Operations was $8.0 billion in Q4 2023, with the low at $1.2 billion in Q2 2022.
• Average Cash from Operations over 5 years is $3.6 billion, with a median of $3.2 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations jumped 422.57% in 2022, then sank 63.5% in 2024.
• Over 5 years, Cash from Operations stood at $7.4 billion in 2022, then grew by 7.49% to $8.0 billion in 2023, then tumbled by 63.5% to $2.9 billion in 2024, then fell by 19.44% to $2.3 billion in 2025, then increased by 22.33% to $2.9 billion in 2026.
• The last three Cash from Operations figures came in at $2.9 billion (Q2 2026), $3.4 billion (Q1 2026), and $2.3 billion (Q4 2025), per Business Quant data.